Earnings Surprises

We delivered another strong quarter, with solid execution across the business led by our market-leading biopreservation media franchise.

Cronos delivered a record second quarter by organically achieving record net revenue, record gross profit and record Adjusted EBITDA, while also reducing our share count. Cronos Israel delivered its tenth consecutive quarter of record net revenue, continuing to secure PEACE NATURALS as the leading cannabis brand in the country. Outside of Israel, our international business also delivered a record net revenue quarter, led by momentum in Germany. In Canada, the Spinach brand continued to gain sign

Our second quarter results exceeded our expectations, demonstrating meaningful progress across agilon's strategic initiatives and reinforcing our confidence in the strength of our Total Care Model.

We are very pleased with how the AMN team executed for our healthcare professionals and clients in the second quarter. Our strong performance produced year-over-year revenue growth in our travel nurse, international nurse, allied, schools, and search solutions.

Oscar delivered record profitability in the first half of the year and we are raising our full-year 2026 guidance. Our superior operating performance and execution against the fundamentals of our strategy are accelerating the individual market.

Acadia delivered an outstanding second quarter, highlighted by strong commercial execution across both DAYBUE and NUPLAZID, resulting in total revenue growth of 17% year-over-year on an adjusted basis.

Innoviva delivered another strong quarter, supported by durable cash generation from our royalty portfolio and continued excellent commercial momentum at IST, which achieved 46% year-over-year net product sales growth, including 26% growth in U.S. sales. We remain on track to achieve at least $150 million in IST U.S. net product sales in 2026, reflecting the differentiation of our marketed critical care and infectious disease portfolio and robust execution.

Our outstanding second quarter reflects the strength of our strategy, the momentum we've built across the business, and the exceptional team driving Omada forward.

Our second quarter results and improved full-year outlook represent meaningful milestones on our path to restoring profitability and increasing shareholder value.

Our strong second quarter results reflect the continued strength of the ZORYVE franchise, the leading branded non-steroidal therapy across our three indications. With our investment in expanding our dermatology sales force and initiatives designed to simplify patient access, we are well positioned to drive continued growth and momentum through the second half of 2026.

Eton reported another outstanding quarter, delivering 99% year-over-year revenue growth, reflecting the strength of our rare disease portfolio and the exceptional execution of our team.

This was an outstanding second quarter and first half of 2026 for LifeStance, as we delivered quarterly revenue growth of 26%, positive net income of $24 million, and Adjusted EBITDA margins of 15%.

We are pleased with our progress this quarter, which reflects disciplined execution against our key strategic priorities to support a return to growth and reinforces our conviction in our short stay surgical platform.

Our second-quarter results exceeded expectations on both the top and bottom lines, driven by both operating performance and an additional benefit from a tariff refund that was not previously contemplated in our guidance.

In the second quarter of 2026, we delivered 9% constant currency revenue growth and 7% adjusted EBITDA growth, reflecting continued execution of our strategy to drive long-term, profitable growth through an expanding and clinically differentiated product portfolio.

This was a record quarter, with approximately 59,200 clinical cases, up more than 12% sequentially, reflecting sustained demand and the payoff from investments in our commercial engine.

As I transition to the CEO role, I’m looking forward to building on the momentum of key initiatives launched during my COO tenure as well as Ardent's strong foundation in attractive, growing markets.

I am honored to write to you for the first time as Chief Executive Officer of STAAR and grateful for the opportunity to lead this talented organization.

Fiscal 2026 was an exceptional year for InnovAge and reflects the significant progress we have made strengthening the company. We enter Fiscal 2027 in a strong position.

This second quarter was about continuing to execute on our commitments. Overall, we are pleased with our ongoing progress transforming Certara into a company we believe can deliver sustainable double-digit growth.

Our focus on the Artegraft international launch paid off in Q2. The product is now approved in 56 countries, accounting for 21% of sales. So our largest product is now our fastest-growing product. To underpin the Artegraft launch and pave the way for RFA, we continue to build our sales force, go direct in new countries and we’re now undertaking six international warehouse expansions. $376m of cash provides strategic optionality.

Our second quarter results highlight strong execution and momentum across the business, delivering 16% year-over-year total revenue growth and driving a considerable increase to our full-year revenue guidance.

We're proud that our clinical AI assistant, Doximity Ask, was the top-performing U.S.-based model in the NOHARM benchmark while we delivered another quarter of record engagement.

We delivered another strong quarter ahead of expectations, generating $213 million in revenue with 53% year-over-year growth, while more than tripling free cash flow from a year ago.